https://vettapharma.com/pharmaceutical-news/mercks-precem-tct-begins-phase-3-for-metastatic-colorectal-cancer-1020-patients-planned/ 2026-05-25T08:28:14Z VETTAPHARMA en Merck's Precem-TcT begins Phase 3 for metastatic colorectal cancer, 1,020 patients planned 2026-05-25T08:28:09Z Blog https://vettapharma.com/pharmaceutical-news/takeda-updates-amitiza-antitrust-jury-verdict-and-revises-fiscal-2025-financial-results/ 2026-05-25T08:25:07Z VETTAPHARMA en Takeda updates Amitiza antitrust jury verdict and revises fiscal 2025 financial results 2026-05-25T08:25:03Z Blog https://vettapharma.com/pharmaceutical-news/lillys-foundayo-shows-up-to-13-weight-loss-in-older-adults-65/ 2026-05-25T08:20:05Z VETTAPHARMA en Lilly's Foundayo shows up to 13% weight loss in older adults 65+ 2026-05-25T08:20:01Z Blog https://vettapharma.com/pharmaceutical-news/ucbs-bimzelx-shows-superior-acr50-versus-skyrizi-in-psoriatic-arthritis-week-16/ 2026-05-25T08:13:21Z VETTAPHARMA en UCB's BIMZELX shows superior ACR50 versus SKYRIZI in psoriatic arthritis Week 16 2026-05-25T08:13:16Z Blog https://vettapharma.com/pharmaceutical-news/ema-accepts-tevas-maa-for-olanzapine-lai-tev-749-for-adult-schizophrenia-treatment/ 2026-05-25T08:05:33Z VETTAPHARMA en EMA accepts Teva's MAA for olanzapine LAI TEV‑749 for adult schizophrenia treatment 2026-05-25T08:05:29Z Blog https://vettapharma.com/pharmaceutical-news/abbvies-maviret-recommended-by-chmp-for-acute-hepatitis-c-with-96-svr12/ 2026-05-25T07:59:27Z VETTAPHARMA en AbbVie’s MAVIRET recommended by CHMP for acute hepatitis C with 96% SVR12 2026-05-25T07:59:23Z Blog https://vettapharma.com/pharmaceutical-news/ema-cvmp-backs-multiple-veterinary-vaccines-and-updates-including-librela-adverse-events/ 2026-05-25T07:55:46Z VETTAPHARMA en EMA CVMP backs multiple veterinary vaccines and updates including Librela adverse events 2026-05-25T07:55:42Z Blog https://vettapharma.com/pharmaceutical-news/gileads-hepcludex-gains-fda-approval-for-chronic-hepatitis-d-showing-48-response/ 2026-05-25T07:52:24Z VETTAPHARMA en Gilead's Hepcludex gains FDA approval for chronic hepatitis D, showing 48% response 2026-05-25T07:52:20Z Blog https://vettapharma.com/pharmaceutical-news/astrazenecas-camizestrant-plus-cdk4-6-reduces-progression-risk-56-in-esr1-mutant-breast-cancer/ 2026-05-25T07:48:07Z VETTAPHARMA en AstraZeneca's camizestrant plus CDK4/6 reduces progression risk 56% in ESR1-mutant breast cancer 2026-05-25T07:48:03Z Blog https://vettapharma.com/pharmaceutical-news/astrazenecas-key-findings-at-asco-2026-innovations-in-oncology/ 2026-05-25T07:47:58Z VETTAPHARMA en AstraZeneca's Key Findings at ASCO 2026: Innovations in Oncology 2026-05-25T07:47:54Z Blog https://vettapharma.com/pharmaceutical-news/sun-pharma-q4fy26-sales-rs145598mn-up-13-6-yoy-net-profit-rises-26-2/ 2026-05-25T07:35:51Z VETTAPHARMA en Sun Pharma Q4FY26 sales Rs145,598mn up 13.6% YOY; net profit rises 26.2% 2026-05-25T07:35:47Z Blog https://vettapharma.com/pharmaceutical-news/astrazenecas-enhertu-recommended-by-chmp-for-her2-positive-solid-tumours-high-response-rates/ 2026-05-25T07:30:48Z VETTAPHARMA en AstraZeneca’s Enhertu recommended by CHMP for HER2-positive solid tumours, high response rates 2026-05-25T07:30:43Z Blog https://vettapharma.com/pharmaceutical-news/astrazenecas-datroway-approved-in-us-for-1st-line-tnbc-extends-overall-survival-benefit/ 2026-05-25T07:25:27Z VETTAPHARMA en AstraZeneca’s Datroway approved in US for 1st-line TNBC, extends overall survival benefit 2026-05-25T07:25:22Z Blog